Physician profile
Chadwin L Fleming
NPI 1659334142
$1,066.56
in general payments reported to CMS, 2019-2025
13 companies · $83.97 in 2025
The $83.97 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.38 · 2020: $39.70 · 2021: $113 · 2022: $114 · 2023: $216 · 2024: $406 · 2025: $83.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $343.06 | 2023-2025 | |
| Astellas Pharma US INC | $122.55 | 2024 | Izervay |
| Apellis Pharmaceuticals, INC. | $122.12 | 2024 | Syfovre |
| Alcon Vision LLC | $109.43 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $100.23 | 2020-2022 | |
| Oyster Point Pharma, INC. | $83.79 | 2022 | |
| Sun Pharmaceutical Industries INC. | $42.40 | 2021-2023 | Cequa |
| Bausch & Lomb Americas INC. | $31.75 | 2024-2025 | Miebo |
| Johnson & Johnson Vision Care, INC. | $29.92 | 2021-2024 | |
| Tarsus Pharmaceuticals, INC. | $28.13 | 2025 | Xdemvy |
| Lkc Technologies, INC. | $24.76 | 2025 | |
| Kala Pharmaceuticals, INC. | $18.26 | 2021 | |
| Maculogix, INC. | $10.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chadwin Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.